ClinicalTrials.gg
CompletedNCT00322387Updated Mar 13, 2014Results posted

Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma Patients

A Phase 2 interventional study of G-CSF and plerixafor in Lymphoma, Non-Hodgkin and Multiple Myeloma, sponsored by Genzyme, a Sanofi Company. Completed at 5 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-03-13.

Sponsored by Genzyme, a Sanofi Company (part of Sanofi) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin — 1 open to participants now, 1 under way, none of them phase 3. Granulocyte Colony-Stimulating Factor · Lymphoma, Non-Hodgkin.

Enrollment
9th of 19
40 · median 36
Started
2004
with 4 others
Phase 2
15 of 19
1 open now
Registered
3rd of 19
by date
Lead sponsor
8 of 19
Genzyme, a Sanofi Company

Among the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, this one is the 9th largest by enrollment, is one of 5 that started in 2004, is one of 15 in phase 2, and was the 3rd registered.

Lymphoma, Non-Hodgkin

2,287 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 286 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

1 of the 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

About Granulocyte Colony-Stimulating Factor

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 245 Lymphoma, Non-Hodgkin studies recruiting now, 145 (59%) set no upper age limit and 77 (31%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Granulocyte Colony-Stimulating Factor in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

Patients with multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) will be mobilized with chemotherapy and G-CSF plus plerixafor (AMD3100). The purpose of this protocol is to determine if plerixafor given after chemotherapy and G-CSF mobilization regimen is safe, if it can increase the circulating levels of peripheral blood stem cells (PBSCs) by ≥ 2-fold before apheresis, and if transplantation with the apheresis product was successful, as measured by time to engraftment of polymorphonuclear leukocytes (PMNs) and platelets (PLTs).

Read the detailed description

An open label, multi-center, phase 2 study was conducted in patients with MM or NHL who were to be treated with peripheral blood stem cells (PBSC) autologous transplantation. The only change to the standard of care was the addition of plerixafor to a mobilization regimen of chemotherapy and G-CSF. Patients were first given a mobilizing regimen of chemotherapy as per local practice guidelines and G-CSF (at customary doses) and apheresis was performed. After the first apheresis, plerixafor was given at 10PM, 10-11 hours before the second apheresis the next day or in the morning of the second day, 6 hours before the second apheresis. The change in the patient's peripheral CD34+ cell count between the plerixafor dose and the start of apheresis was measured. The apheresis yields on Day 1 and Day 2 were compared.

This study was previously posted by AnorMED, Inc. In November 2006, AnorMED, Inc. was acquired by Genzyme Corporation. Genzyme Corporation is the sponsor of the trial.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
  • Multiple Myeloma

Keywords

  • Non-Hodgkin's Lymphoma
  • Multiple Myeloma
  • Stem cell mobilization
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • MM in first partial response/complete response, first relapse, or second partial/complete response
  • NHL in first or second partial or complete remission
  • NHL patients who do not have bone marrow involvement and \< 10% for follicular involvement
  • MM patients who have stable disease with \< 40% bone marrow involvement
  • No more than three prior regimens of chemotherapy (thalidomide and Decadron are not considered chemotherapy)
  • (ECOG) performance status of 0 or 1
  • White blood cell count (WBC) >3.0 x 10\^9/L
  • >1.5 x 10\^9/L
  • count >100 x 10\^9/L

Exclusion criteria

Exclusion Criteria (Abbreviated List):

  • or carcinomatous meningitis
  • Hypercalcaemia [>1 mg/dl above the (ULN)]
  • Cardiovascular disease that includes proven or predisposition to ventricular arrhythmias
  • Acute Infection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Plerixafor PM

    Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. After the first apheresis, plerixafor (240 µg/kg) was administered each evening (approximately 10pm) followed by apheresis 10 to 11 hours later for up to 4 consecutive days. Called 'Cohort A' in protocol, study report and publications.

    Drug: G-CSF and plerixafor

  • Experimental
    Plerixafor AM

    Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. When participants achieved a target CD34+ count of ≥20 cells/µL, apheresis began. G-CSF was given daily in the morning on the days of apheresis. The morning of the second day after the first apheresis, plerixafor (240 µg/kg) was administered followed by apheresis 6 hours later. Plerixafor (240 µg/kg) was administered in the morning followed by apheresis 6 hours later for up to 4 consecutive days. Called 'Cohort B' in protocol, study report and publications.

    Drug: G-CSF and plerixafor

  • Experimental
    Low CD34+ Count/ Plerixafor PM

    Participants received chemotherapy and G-CSF mobilization for 7 days according to standard procedures at the study center. If participants had a CD34+ count of \>=10 cells/µL but \<20 cells/µL on 2 consecutive days, plerixafor (240 µg/kg) was given in the evening. G-CSF was administered and apheresis performed in the morning. Plerixafor (240 µg/kg) administered in the evening followed by G-CSF and apheresis 10 to 11 hours later was repeated for up to 4 consecutive days. Called 'Cohort C' in protocol, study report and publications.

    Drug: G-CSF and plerixafor

  • Experimental
    Plerixafor After Chemo

    This investigational cohort evaluated the effect of administering plerixafor before white blood cell recovery. Participants received mobilizing chemotherapy, followed by 5 consecutive days of G-CSF (10 µg/kg). Starting on the sixth day, participants received G-CSF (10 µg/kg) plus plerixafor (240 µg/kg) daily for up to 3 consecutive days. If CD34+ counts reached \>= 20 cells/µL 6 hours after any of the 3 plerixafor doses, apheresis began. If not, G-CSF administration continued until the participant qualified for one of the other treatment arms. Called 'Investigational Cohort' in protocol, study report and publications.

    Drug: G-CSF and plerixafor

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant

    Safety assessment was based on the incidence of adverse event reports. Participant count of AEs (Adverse Events) by severity and by relationship to study drug. AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale and provided assessments of seriousness and relatedness to study treatment.

    Time frame: 13 months

Secondary outcomes

  1. Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL

    The fold increase was measured by fluorescence activated cell sorting (FACS) analysis and was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL).

    Time frame: Days 4-5 (first dose of plerixafor to apheresis)

  2. Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

    Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

    Time frame: 2 months

07

Results

Posted Jul 14, 2010
Limitations and caveats
The number and complexity of the cohorts make generalizations regarding the data problematic. Each cohort was small, and mobilizing and high-dose conditioning regimens varied across sites. AEs may include residual effects of chemotherapy.

Participant flow

Patients with NHL or MM eligible for the study were recruited from 5 centers in the United States. The first patient was enrolled (signed informed consent) in April 2004 and the last patient's last study visit was July 2006.

Treatment Period
Participant flow — Treatment Period
MilestoneNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
Started1426
Completed1425
Not completed01
Withdrew: Adverse event01
Follow-up Period
Participant flow — Follow-up Period
MilestoneNon-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)
Started1426
Completed1223
Not completed23
Withdrew: Final assessment not done13
Withdrew: Death10

Outcome measures

PrimaryOverall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant

Safety assessment was based on the incidence of adverse event reports. Participant count of AEs (Adverse Events) by severity and by relationship to study drug. AEs were reported regardless of relationship to study treatment. The investigator graded each AE using the World Health Organization (WHO) Adverse Event Grading Scale and provided assessments of seriousness and relatedness to study treatment.

Time frame:
13 months
Reported as:
Number · participants
Overall Participant Counts of Adverse Events (AEs) Up to Twelve Months Post Transplant
participantsNon-Hodgkin's Lymphoma (NHL): Plerixafor PMNon-Hodgkin's Lymphoma (NHL): Plerixafor AMNon-Hodgkin's Lymphoma (NHL): Plerixafor After ChemoMultiple Myeloma (MM): Plerixafor PMMultiple Myeloma (MM): Plerixafor AMMultiple Myeloma (MM): Low CD34+ Count/Plerixafor PMMultiple Myeloma (MM): Plerixafor After ChemoAll Participants
Participants reporting ≥ 1 Adverse Event7611291339
AE Severity (Mild)330220010
AE Severity (Moderate)211630215
AE Severity (Severe)220441114
AE Severity (Life Threatening)11023007
AE Relationship to Drug (Not related)05002029
AE Relationship to Drug (Probably not related)30030006
AE Relationship to Drug (Possibly related)10035009
AE Relationship to Drug (Probably related)11131007
AE Relationship to Drug (Definitely related)20031118
SecondaryFold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL

The fold increase was measured by fluorescence activated cell sorting (FACS) analysis and was expressed as a ratio. Fold increase = (pre-apheresis PB CD34+ cells/µL)/(pre-plerixafor dosing PB CD34+ cells/µL).

Time frame:
Days 4-5 (first dose of plerixafor to apheresis)
Reported as:
Mean · ratio
Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL
ratioNon-Hodgkin's Lymphoma (NHL): Plerixafor PMNon-Hodgkin's Lymphoma (NHL): Plerixafor AMNon-Hodgkin's Lymphoma (NHL): Plerixafor After ChemoMultiple Myeloma (MM): Plerixafor PMMultiple Myeloma (MM): Plerixafor AMMultiple Myeloma (MM): Low CD34+ Count/Plerixafor PMMultiple Myeloma (MM): Plerixafor After Chemo
Fold (i.e., Relative) Increase in Peripheral Blood (PB) CD34+ Cells/µL2.2 ± 0.81.5 ± 0.81.2 ± 0.01.8 ± 0.46.5 ± 14.724.0 ± 0.03.1 ± 0.0
SecondaryNumber of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant

Participants were monitored for polymorphonuclear leukocyte (PMN) engraftment as per the local standard of care. The target for engraftment was 12 days after PBSC transplant and no transplant taking longer than 21 days for engraftment.

Time frame:
2 months
Reported as:
Number · transplants
Number of Transplants in Which Participants Achieved Polymorphonuclear Leukocyte (PMN) Engraftment by Day 12 But No Later Than Day 21 Post Peripheral Blood Stem Cell (PBSC) Transplant
transplantsNon-Hodgkin's Lymphoma (NHL): Plerixafor PMNon-Hodgkin's Lymphoma (NHL): Plerixafor AMNon-Hodgkin's Lymphoma (NHL): Plerixafor After ChemoMultiple Myeloma (MM): Plerixafor PMMultiple Myeloma (MM): Plerixafor AMMultiple Myeloma (MM): Low CD34+ Count/Plerixafor PMMultiple Myeloma (MM): Plerixafor After Chemo
≤ Day 1264014910
Day 13 to Day 211210314
≥ Day 220000000

Adverse events

Collected over Treatment Period includes the first day of G-CSF mobilization to the day prior to chemotherapy/ablative treatment in preparation for the first transplant. This period includes G-CSF administration, the plerixafor dose, and the rest period.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Non-Hodgkin's Lymphoma (NHL): Plerixafor PM—1/7 (14.3%)7/7 (100%)
Non-Hodgkin's Lymphoma (NHL): Plerixafor AM—0/6 (0%)6/6 (100%)
Non-Hodgkin's Lymphoma (NHL): Plerixafor After Chemo—0/1 (0%)1/1 (100%)
Multiple Myeloma (MM): Plerixafor PM—2/12 (16.7%)12/12 (100%)
Multiple Myeloma (MM): Plerixafor AM—2/9 (22.2%)9/9 (100%)
Multiple Myeloma (MM): Low CD34+ Count/Plerixafor PM—0/1 (0%)1/1 (100%)
Multiple Myeloma (MM): Plerixafor After Chemo—1/4 (25%)2/4 (50%)
Most frequent serious events
Most frequent serious events
EventNon-Hodgkin's Lymphoma (NHL): Plerixafor PMNon-Hodgkin's Lymphoma (NHL): Plerixafor AMNon-Hodgkin's Lymphoma (NHL): Plerixafor After ChemoMultiple Myeloma (MM): Plerixafor PMMultiple Myeloma (MM): Plerixafor AMMultiple Myeloma (MM): Low CD34+ Count/Plerixafor PMMultiple Myeloma (MM): Plerixafor After Chemo
Febrile neutropeniaBlood and lymphatic system disorders1/70/60/11/122/90/11/4
Staphylococcal sepsisInfections and infestations1/70/60/10/120/90/10/4
NauseaGastrointestinal disorders0/70/60/11/120/90/10/4
VomitingGastrointestinal disorders0/70/60/11/120/90/10/4
Cystitis haemorrhagicRenal and urinary disorders0/70/60/11/120/90/10/4
Most frequent other events
Showing 10 of 93
Most frequent other events
EventNon-Hodgkin's Lymphoma (NHL): Plerixafor PMNon-Hodgkin's Lymphoma (NHL): Plerixafor AMNon-Hodgkin's Lymphoma (NHL): Plerixafor After ChemoMultiple Myeloma (MM): Plerixafor PMMultiple Myeloma (MM): Plerixafor AMMultiple Myeloma (MM): Low CD34+ Count/Plerixafor PMMultiple Myeloma (MM): Plerixafor After Chemo
Vision blurredEye disorders0/70/60/10/120/91/10/4
Anal fistulaGastrointestinal disorders0/70/61/10/120/90/10/4
DiarrhoeaGastrointestinal disorders2/71/60/16/123/91/10/4
HaemorrhoidsGastrointestinal disorders0/70/61/10/120/90/10/4
Hypoaesthesia oralGastrointestinal disorders1/70/60/11/121/91/10/4
Rectal fissureGastrointestinal disorders0/70/61/10/120/90/10/4
Catheter site erythemaGeneral disorders0/70/61/10/120/90/10/4
Injection site urticariaGeneral disorders0/70/60/10/120/91/10/4
Pain in extremityMusculoskeletal and connective tissue disorders1/70/61/11/120/90/10/4
HeadacheNervous system disorders5/70/61/12/123/91/10/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Mean54.7 ± 10.856.1 ± 7.655.6 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Female81119
Male61521
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Non-Hodgkin's Lymphoma (NHL)Multiple Myeloma (MM)Total
Hispanic or Latino022
Not Hispanic or Latino142438
Unknown or Not Reported000
08

Study locations

5 sites
  • City of Hope National Medical Center
    Duarte, California, United States
  • Indiana Blood and Marrow Transplantation
    Beech Grove, Indiana, United States
  • University of Rochester Medical Center
    Rochester, New York, United States
  • Oregon Health and Science University
    Portland, Oregon, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington, United States
09

References and documents

Publications

  • Dugan MJ, Maziarz RT, Bensinger WI, Nademanee A, Liesveld J, Badel K, Dehner C, Gibney C, Bridger G, Calandra G. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant. 2010 Jan;45(1):39-47. doi: 10.1038/bmt.2009.119. Epub 2009 Jun 1. PubMed 19483760 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2004, a primary completion of Jul 2006 and a completion of Jul 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 4 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2006
First posted
May 5, 2006
Start
Apr 2004
Primary completionActual
Jul 2006
CompletionActual
Jul 2006
Results first posted
Jul 14, 2010
Last update
Mar 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00322387
First posted
May 5, 2006
Start date
Apr 2004
Primary completion
Jul 2006
Completion
Jul 2006
Results posted
Jul 14, 2010
Last update
Mar 13, 2014

Study contacts

Medical Monitor
study director · Genzyme, a Sanofi Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Granulocyte Colony-Stimulating Factor · Plerixafor

Start the discussion